To read the full story, subscribe or sign in.

Takeda validates Crescendo’s platform to the tune of $790M

Oct. 12, 2016

LONDON – Crescendo Biologics Ltd. has landed the first major partner for its Humabody pared back antibody constructs, agreeing to an oncology collaboration worth up to $790 million with Osaka, Japan-based Takeda Pharmaceuticals Ltd.

BioWorld Asia

Today's news in brief

BioWorld

BioWorld briefs for March 16, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...